Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The CooperCOO -1.49%88 Intrinsic Value: Projected FCF is $57.41 as of Sep. 08, 2026. GuruFocus rates COO with a GF Score™ of 88/100 and a GF Value™ of $102.12 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 414 Medical Devices & Instruments companies, The Cooper ranks better than 61.35% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-09-08), The Cooper's Intrinsic Value: Projected FCF is $57.41. The stock price of The Cooper is $69.59. Therefore, The Cooper's Price-to-Intrinsic-Value-Projected-FCF of today is 1.2.
The historical rank and industry rank for The Cooper's Intrinsic Value: Projected FCF or its related term are showing as below:
COO'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 1.1 Med: 1.88 Max: 2.26
Current: 1.21
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of The Cooper was 2.26. The lowest was 1.10. And the median was 1.88.
COO's Price-to-Projected-FCF is ranked better than 61.35% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 1.505
vs COO: 1.21
The Cooper (NAS:COO) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
The Cooper's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
69.59
/
57.409317815788
=
1.21
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Cooper Intrinsic Value: Projected FCF Related Terms
The Cooper Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for The Cooper's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COO vs BAX, SOLV, ALGN: Intrinsic Value: Projected FCF Comparison
For the Medical Instruments & Supplies subindustry, The Cooper's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper Price-to-Projected-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where The Cooper's Price-to-Projected-FCF falls into.
The Cooper Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $57.41 mean?
The Cooper (COO) has a Intrinsic Value: Projected FCF of $57.41 as of Sep. 08, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on The Cooper and its competitors. According to the industry distribution chart, The Cooper ranks #160 out of 414 companies in the Medical Devices & Instruments industry, placing it in the top 38.6%.
Is The Cooper's Intrinsic Value: Projected FCF too high?
The Cooper's current Intrinsic Value: Projected FCF is $57.41. The Medical Devices & Instruments industry median Intrinsic Value: Projected FCF is 1.51. The Cooper's value of $57.41 is 3714.6% above this industry median. Based on the distribution chart, The Cooper ranks #160 out of 414 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, The Cooper has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's Intrinsic Value: Projected FCF compare to BAX and SOLV?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #160 out of 414 companies for Intrinsic Value: Projected FCF. This puts The Cooper in the upper half of its industry. The industry median Intrinsic Value: Projected FCF is 1.51. The Cooper's value of $57.41 is 3714.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Devices & Instruments company?
The median Intrinsic Value: Projected FCF among Medical Devices & Instruments companies is 1.51, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Cooper's current Intrinsic Value: Projected FCF of $57.41 is 3714.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on The Cooper and its competitors. For the Medical Devices & Instruments industry, the median Intrinsic Value: Projected FCF is 1.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current Intrinsic Value: Projected FCF is $57.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Significantly Undervalued. The stock's GF Value™ is $102.12, compared to a current price of $69.59 — trading 31.9% below its estimated fair value. The current Intrinsic Value: Projected FCF is $57.41 and 3714.6% above the Medical Devices & Instruments industry median of 1.51. The Cooper's overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For The Cooper (COO), the current Intrinsic Value: Projected FCF is $57.41 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of $69.59 is trading 31.9% below its estimated GF Value™ of $102.12.
GuruFocus considers The Cooper to be Significantly Undervalued.
Key valuation signals for COO:
Intrinsic Value: Projected FCF: $57.41
GF Value™: $102.12 vs. price of $69.59 (31.9% below fair value)
Industry Position: 3714.6% above the Medical Devices & Instruments median (#160 of 414)
No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
88GF Score
Get the complete analysis for COO
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COO has been successfully added to your 
